Aim To investigate the effects of estrogen-related events (age at menopause, age at menarche) on later-life skeletal fragility in Bosnian postmenopausal women. Methods A total of 100 postmenopausal Bosnian women, aged between 55 and 75 years, were included. The women in the study group (n=50) had fragility fractures, and in the control group (n=50) were without fragility fractures. Bone mineral density (BMD) was measured using Dual Energy X-ray Absorptiometry (DXA) on the lumbar spine (L2-L4) and proximal femur. Results No statistically significant difference relating to the age between the groups was found. The average age at menopause was 44.70 years in women with fragility fractures and 51.76 years in women without fragility fracture (p=0.0001). The average age at menarche was 14.30 years in women with fragility fractures and 13.70 years in women without fragility fractures (p=0.140). T score of ≤-2.5 SD was found in 40 (80%) women in the study group, and in eight (16%) women in the control group (p=0.0001). Conclusions Age at menopause, but not age at menarche, was risk factors for later-life fragility fracture in postmenopausal Bosnian women. In addition, fragility fractures correlated with low BMD in this population group.
Vesco KK, Marshall LM, Nelson HD, Humphrey L, Rizzo J, Pedula KL, et al. Study of osteoporotic fractures. Surgical menopause and nonvertebral fracture risk among older US women. Menopause 2012;19:510–6.
2
Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 2005;20:185–94.
3
Kanis JA, Johnell O, Leat C, Jonsson B, Oden A, Ogelsby AK. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 2002;17:1237–44.
4
Lo JC, Chandra M, Lee DR, Darbinian JA, Gordon NP, Zeltser DW, et al. Sex- and ethnic-specific patterns in the incidence of hip fracture among older US Asian and non-Hispanic white adults. J Am Geriatr Soc 2023;71:1910–6.
5
Cauley JA. Defining ethnic and racial differences in osteoporosis and fragility fractures. Clin Orthop Relat Res 2011;469:1891–9.
6
Mayhew PM, Thomas CD, Clement JG, Loveridge N, Beck TJ, Bonfield W, et al. Relation between age, femoral neck cortical stability, and hip fracture risk. Lancet 2005;366:129–35.
7
Kanis JA, Cooper C, Rizzoli R, Abrahamsen B, AlDaghri NM, Brandi ML, et al. European Society for Clinical and Economic Aspects of Osteoporosis. Osteoarthritis and Musculoskeletal Diseases (ESCEO). Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 2017, vol. 28, n.d., p. 2023–34.
8
Yoo JE, Shin DW, Han K, Kim D, Yoon JW, Lee DY. Association of female reproductive factors with incidence of fracture among postmenopausal women in Korea. JAMA Netw Open 2021;4:e2030405.
9
MA AA, HS S, MF A, WW A, AH MM, WE AE. Proportion and risk factors of silent vertebral fractures among Egyptian females with fragility hip fracture presenting to the emergency room of Ain Shams University Hospitals. Cureus 2023:15 46214.
10
Farahmand M, Rahmati M, Azizi F, Gandevani BS, Tehrani RF. The impact of endogenous estrogen exposure duration on fracture incidence: a longitudinal cohort study. J Clin Endocrinol Metab 2022;107:e3321-9.
11
Kotsopoulos J, Hall E, FinchA H, H M, J R, B N, et al. Changes in bone mineral density after prophylactic bilateral salpingo-oophorectomy in carriers of a BRCA mutation. Psychooncology 2013;22:212–9.
12
Anagnostis P, Siolos P, NK G, Kosmidou N, AM A, K C, et al. Association between age at menopause and fracture risk: a systematic review and meta-analysis. Endocrine 2019;63:213–24.
13
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group Geneva, World Health Organization, 1994 (WHO Technical Report Series n.d.;(843)).
14
Fakkert IE, Teixeira N, EM A, Slart R, Mourits M, Bock GH. Bone mineral density and fractures after surgical menopause: systematic review and meta-analysis. BJOG 2017;124:1525–35.
15
Lu L, Tian L. Postmenopausal osteoporosis coexisting with sarcopenia: the role and mechanisms of estrogen. J Endocrinol 2023;259:e230116.
16
Paganini-Hill A, Atchison KA, Gornbein JA, Nattiv A, Service SK, White SC. Menstrual and reproductive factors and fracture risk: the leisure world cohort study. J Womens Health (Larchmt 2005;14:808–19.
17
Shieh A, Ruppert KM, Greendale GA, Lian Y, Cauley JA, Burnett-Bowie SA, et al. Associations of age at menopause with postmenopausal bone mineral density and fracture risk in women. J Clin Endocrinol Metab 2022;107:e561-9.
18
Long G, Liu C, Liang T, Zhang Z, Qin Z, Zhan X. Predictors of osteoporotic fracture in postmenopausal women: a meta-analysis. J Orthop Surg Res 2023;18;(574).
19
Seeman E, Delmas PD. Bone quality: the material and structural basis of bone strength and fragility. N Engl J Med 2006;354:2250–61.
20
Wang LT, Chen LR, Chen KH. Hormone-related and drug-induced osteoporosis: a cellular and molecular overview. Int J Mol Sci 2023;24;(5814).
21
Clarke BL, Khosla S. Female reproductive system and bone. Arch Biochem Biophys 2010;503:118–28.
22
Williams C, Sapra A. Osteoporosis markers. Updated 2023.
23
Song S, Guo Y, Yang Y, Fu D. Advances in pathogenesis and therapeutic strategies for osteoporosis. Pharmacol Ther 2022;237;(108168).
24
Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 2021;16;(82).
25
Tran T, Ho-Le T, Bliuc D, Abrahamsen B, Hansen L, Vestergaard P, et al. “Skeletal Age” for mapping the impact of fracture on mortality. Elife 2023;12:e83888.
26
Ratti C, Vulcano E, Canton G, Marano M, Murena L, Cherubino P. Factors affecting bone strength other than osteoporosis. Aging Clin Exp Res 2013;25;(Suppl 1).
27
Brown JP, Josse RG. clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167;(10 Suppl).
28
Iolascon G, Paoletta M, Liguori S, Gimigliano F, Moretti A. Bone fragility: conceptual framework, therapeutic implications, and COVID19-related issues. Ther Adv Musculoskelet Dis 2022;14;(1759720).
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
